Natera (NTRA) has filed a lawsuit in the North Carolina Federal District Court against NeoGenomics Labs (NEO) for infringement of Natera’s U.S. Patent Nos. 11,519,035 and 11,530,454 by NeoGenomics’ RaDaR molecular residual disease assay. This lawsuit builds on Natera’s current patent infringement lawsuit in the United States District Court for the District of Delaware related to RaDaR tests sold by Inivata, an affiliate of NeoGenomics. The company’s filing of this new suit follows a recent jury verdict in favor of Natera in the U.S. District Court for the District of Delaware in the patent infringement suit it filed against ArcherDX/Invitae Corp.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NTRA:
- Natera completes enrollment in ALTAIR trial
- Craig-Hallum says CareDx appears to look to Congress for help amid Castle reversal
- CareDx announces district court upholds March 2022 jury verdict against Natera
- Natera announces ruling in favor of the company in CareDx false advertising case
- CareDx, Natera may have precedent to rebuke MolDx, says Craig-Hallum